Sellas Life Sciences Group Inc
SLS
NASDAQ
Biotechnology
$12.78
USD
+0.42 (+3.40%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.46B
Volume 4.4M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-32.46M
TTM
-23.6%
YoY
Operating Cash Flow
$-28.42M
TTM
+9.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.0 | 2.9 | 3.5 | 4.1 | 4.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.9 | 7.1 | 8.3 | 9.3 | 10.6 |
Operating Income | -6.9 | -7.1 | -8.3 | -9.3 | -10.6 |
EBITDA | -6.9 | -7.1 | -8.3 | -9.3 | -10.6 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.3 | 0.3 | 0.6 | 0.8 | 1.0 |
Income Before Income Taxes | -6.6 | -6.8 | -7.7 | -8.4 | -9.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.6 | -6.8 | -7.7 | -8.4 | -9.6 |
Consolidated Net Income / Loss | -6.6 | -6.8 | -7.7 | -8.4 | -9.6 |
Net Income Attributable to Common Shareholders | -6.6 | -6.8 | -7.7 | -8.4 | -9.6 |
Basic EPS | -$0.07 | -$0.06 | -$0.05 | -$0.05 | -$0.05 |
Diluted EPS | -$0.07 | -$0.06 | -$0.05 | -$0.05 | -$0.05 |
Basic Shares Outstanding | 98.6M | 108.4M | 141.5M | 172.5M | 189.2M |
Diluted Shares Outstanding | 98.6M | 108.4M | 141.5M | 172.5M | 189.2M |